This article requires a subscription to view the full text. You may purchase access to this article or login to access your subscription using the links below.
Abstract
A phase II trial shows that a chemotherapy-free regimen of dasatinib and blinatumomab produces molecular responses in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia. The study found that 60% of patients had molecular responses after two cycles of blinatumomab and 71% had molecular responses after five cycles.
- ©2020 American Association for Cancer Research.
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
December 2020
Volume 10, Issue 12
Volume 10, Issue 12
Drug Combo May Obviate Chemotherapy in ALL
Jump to section
Advertisement